Systemic Lupus Erythematosus Clinical Trial
— NET-SSCOfficial title:
Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis
Systemic sclerosis (SSC) is a systemic disease characterized by limited or diffuse cutaneous
sclerosis, microangiopathy, overproduction of autoantibodies and variable organ damage due to
vasculopathy and/or fibrosis. The loss of self-tolerance is believed to be caused by the
dysregulation of both innate and adaptive immune systems and may involve reactive oxygen
species (ROS).
Neutrophils are potent producers of ROS and may play a role in endothelial cells and
fibrobasts dysfunction, as in autoantibodies generation. However, their role in SSC
pathogenesis remains to be determined. Recent studies discovered abnormal regulation of
neutrophil extracellular traps (NETs) in other auto-immune diseases such as systemic lupus
erythematosus (SLE). NETs are web-like structures composed of chromatin backbones and
granular molecules. They are released by activated neutrophils through a process called
"NETosis". Nets were first described in 2004 as a novel host defense mechanism to trap and
kill foreign pathogens. Recent evidence shows that NETs also participate in the pathogenesis
of a variety of inflammatory and autoimmune diseases, including SLE.
We hypothesis that this phenomenon could be dysregulated in SSC as in SLE and could play a
prominent role in the induction of autoimmunity, as well as in the induction and perpetuation
of organ damages.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | October 7, 2021 |
Est. primary completion date | October 6, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: for patients of arm 1: - patients with systemic lupus erythematosus - patients consenting to participate to the study - patients enrolled in the national healthcare insurance program for patients of arm 2: - patients with systemic sclerosis - patients consenting to participate to the study - patients enrolled in the national healthcare insurance program For patients of arm 3 (healthy volunteers) - Patients without Chronic inflammatory systemic disease - Patients without Current or past neoplasy, - patients without chronic metabolic pathology - patients without treatment by anti inflammatory or corticotherapy for the last 15 days, - patients without infectious pathology or inflammatory acute for the last 15 days |
Country | Name | City | State |
---|---|---|---|
France | Damien JOLLY | Reims |
Lead Sponsor | Collaborator |
---|---|
CHU de Reims |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quantification of neutrophil extracellular traps (NETs) generated after stimulation of neutrophils in vitro by serum from SSC, SLE and healthy controls. | Comparative analysis of the quantity of neutrophil extracellular traps (NETs) generated after stimulation of neutrophils in vitro by serum from SSC, SLE and healthy controls. Neutrophils from SSC, SLE and healthy subjects will be used. | Day 0 | |
Secondary | Analysis of the composition of neutrophil extracellular traps | Comparative analysis of the composition of neutrophil extracellular traps (NETs) generated after stimulation of neutrophils in vitro by serum from SSC, SLE and healthy controls. Neutrophils from SSC, SLE and healthy subjects will be used. | Day 0 | |
Secondary | Analysis of the cytokines influencing NETs production in vitro | Comparative analysis of the quantity of neutrophil extracellular traps (NETs) generated after stimulation of neutrophils from SSC patients in vitro by differents cytokines | Day 0 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03843125 -
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
|
Phase 3 | |
Recruiting |
NCT05698173 -
Systemic Lupus Erythematosus and Accelerated Aging
|
N/A | |
Active, not recruiting |
NCT01649765 -
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
|
Phase 2 | |
Recruiting |
NCT05704153 -
Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A)
|
N/A | |
Completed |
NCT05048238 -
Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
|
Phase 1 | |
Recruiting |
NCT06056778 -
The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus
|
Phase 1 | |
Completed |
NCT04358302 -
Individual Patient Exposure and Response in Pediatric Lupus
|
N/A | |
Completed |
NCT03802578 -
The Impact of Exercise on Hand Function, Daily Activities Performance and Quality of Life of SLE' Patients
|
N/A | |
Completed |
NCT02554019 -
Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT04835883 -
Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients
|
Phase 2 | |
Terminated |
NCT02665364 -
Phase IIb Study of IFN-K in Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT00278538 -
Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT00069342 -
Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
|
||
Completed |
NCT03252587 -
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
|
Phase 2 | |
Terminated |
NCT02066311 -
Nelfinavir in Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT01892748 -
Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus.
|
N/A | |
Terminated |
NCT01689025 -
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
|
Phase 1 | |
Completed |
NCT01475149 -
Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
|
N/A | |
Unknown status |
NCT01712529 -
Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients
|
N/A |